文献速递肿瘤 PET/CT核素与放射性配体治疗

纳入PSMA PET信息的列线图预测前列腺癌淋巴结受累的外部验证

External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-02

本研究纳入437例经组织学确诊的前列腺癌患者,在根治性前列腺切除术和扩大盆腔淋巴结清扫前接受MRI和PSMA PET/CT,外部验证四种包含PSMA PET参数的淋巴结受累列线图及Briganti 2012和MSKCC列线图。Amsterdam-Brisbane-Sydney模型区分度最高(AUC 0.81),其次为Muehlematter模型1(AUC 0.79),两者校准良好但各阈值下存在轻微系统性风险高估;MSKCC和Briganti 2012模型AUC分别为0.68和0.67。作者认为外部验证确认了Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图的强模型区分度、中等校准和良好临床效用,支持其作为指导临床决策工具的可靠性。

要点

  • 437例中19.7%(86/437)为pN1,PSMA PET/CT检测淋巴结受累灵敏度47.7%、特异度95.4%。
  • Amsterdam-Brisbane-Sydney模型AUC 0.81最高,Muehlematter模型1 AUC 0.79,两者校准良好但轻微高估风险。
  • 以8%和15%为阈值,Amsterdam-Brisbane-Sydney和Muehlematter模型1分别可使15%和16%患者免于ePLND且不漏诊淋巴结受累。

核心结论

  • 外部验证确认Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图预测淋巴结受累具有强模型区分度、中等校准和良好临床效用,支持其作为指导临床决策工具的可靠性。

研究设计与样本

  • 纳入经组织学确诊的前列腺癌患者,在根治性前列腺切除术和扩大盆腔淋巴结清扫前接受术前MRI和PSMA PET/CT,共437例。
  • 外部验证四种包含PSMA PET参数的淋巴结受累列线图(三种Muehlematter模型和Amsterdam-Brisbane-Sydney模型)及Briganti 2012和MSKCC列线图。
  • 对每个列线图评估模型区分度(AUC)、校准和决策曲线分析的净获益。

主要发现

  • 437例中低危0.7%、中危39.8%、高危59.5%,86/437(19.7%)为pN1。
  • PSMA PET/CT检测淋巴结受累的灵敏度和特异度分别为47.7%(95% CI: 36.8-58.7)和95.4%(95% CI: 92.7-97.4)。
  • Amsterdam-Brisbane-Sydney模型区分度最高(AUC 0.81,95% CI: 0.76-0.86),其次为Muehlematter模型1(AUC 0.79,95% CI: 0.74-0.85),两者校准良好但各阈值下存在轻微系统性风险高估。
  • MSKCC和Briganti 2012模型AUC分别为0.68(95% CI: 0.61-0.74)和0.67(95% CI: 0.61-0.73),两者校准中等。
  • 决策曲线分析显示Amsterdam-Brisbane-Sydney模型在5-20%阈值范围内净获益更优,Muehlematter模型1列线图在14-20%范围内显示获益;以Amsterdam-Brisbane-Sydney列线图8%阈值和Muehlematter模型1 15%阈值,分别可使15%和16%患者免于ePLND且不漏诊淋巴结受累。

关键数值与推荐

  • Amsterdam-Brisbane-Sydney模型AUC 0.81(95% CI: 0.76-0.86),校准良好但各阈值下轻微系统性高估风险。
  • Muehlematter模型1 AUC 0.79(95% CI: 0.74-0.85),校准良好但各阈值下轻微系统性高估风险。
  • MSKCC模型AUC 0.68(95% CI: 0.61-0.74),校准中等;Briganti 2012模型AUC 0.67(95% CI: 0.61-0.73),校准中等。
  • PSMA PET/CT检测淋巴结受累灵敏度47.7%(95% CI: 36.8-58.7),特异度95.4%(95% CI: 92.7-97.4)。
  • Amsterdam-Brisbane-Sydney列线图8%阈值和Muehlematter模型1 15%阈值下,分别15%和16%患者可免于ePLND且不漏诊淋巴结受累。

临床怎么用

  • 作者认为外部验证结果支持Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图作为指导临床决策工具的可靠性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel nomograms predicting lymph node involvement (LNI) of prostate cancer (PCa) including PSMA PET information have been developed. However, their predictive accuracy in external populations is still unclear. PURPOSE: To externally validate four LNI nomograms including PSMA PET parameters (three Muehlematter models and the Amsterdam-Brisbane-Sydney model) as well as the Briganti 2012 and MSKCC nomograms. METHODS: Patients with histologically confirmed PCa undergoing preoperative MRI and PSMA PET/CT before radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) were included. Model discrimination (AUC), calibration and net benefit using decision curve analysis were determined for each nomogram. RESULTS: A total of 437 patients were included, comprising 0.7% with low-risk disease, 39.8% with intermediate-risk disease, and 59.5% with high-risk disease. Among them, 86 out of 437 (19.7%) had pN1 disease. The sensitivity and specificity of PSMA PET/CT for the detection of LNI were 47.7% (95% CI: 36.8-58.7) and 95.4% (95% CI: 92.7-97.4), respectively. Among predictive models, the Amsterdam-Brisbane-Sydney model achieved the highest discrimination (AUC: 0.81, 95% CI: 0.76-0.86), followed by Muehlematter Model 1 (AUC: 0.79, 95% CI: 0.74-0.85), both with good calibration but slight systematic overestimation of risks across all thresholds. The MSKCC and Briganti 2012 models had AUCs of 0.68 (95% CI: 0.61-0.74) and 0.67 (95% CI: 0.61-0.73), respectively, and both had moderate calibration. Decision curve analysis indicated that the Amsterdam-Brisbane-Sydney model provided superior net benefit across thresholds of 5-20%, followed by the Muehlematter Model 1 nomogram showing benefit in the 14-20% range. Using thresholds of 8% for the Amsterdam-Brisbane-Sydney nomogram and 15% for Muehlematter Model 1, ePLND could be spared in 15% and 16% of patients, respectively, without missing any LNI cases. CONCLUSION: External validation of the Muehlematter Model 1 and Amsterdam-Brisbane-Sydney nomograms for predicting LNI confirmed their strong model discrimination, moderate calibration, and good clinical utility, supporting their reliability as tools to guide clinical decision-making.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Van Bergen TD, Braat AJAT, Hermsen R, et al. External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40172694. doi:10.1007/s00259-025-07241-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。